(–)-trans-Cannabidiol, API isolate
Product Description
CBDepot
-
Country/Region:Slovakia
-
On CPHI since:2017
-
Certificates:2
-
Employees:25 - 49
Company types
Specifications
CBDepot
-
Country/Region:Slovakia
-
On CPHI since:2017
-
Certificates:2
-
Employees:25 - 49
Company types
More Products from CBDepot (2)
-
Product (–)-trans-Cannabidiol, PhG isolate
Pharma-GradeSubstance origin: Cannabis sativa L.
Conforms with quality criteria: DAC/NRF 2020/2, C - 052
Certifications: Czech Medicines Agency (SUKL.cz), ISO 9001:2015, ISO 14001:2015 -
Product (–)-trans-Cannabidiol, PhG synthesized
Pharma Grade, Active substance for pharmaceutical use.
Substance origin: chemical synthesis
Conforms with quality criteria: DAC/NRF 2016/2, C-052
CBDepot resources (2)
-
News CBDepot launches the sale of synthesized pharma-grade CBD
CBDepot group starts the marketing of synthesized pharma-grade CBD produced under the EU GMP umbrella of its sister company CB21 Pharma, s.r.o. -
Whitepaper CB21 Pharma, the spin-off sister company to CBDepot, successfully extends EU GMP certification to broaden its cannabis-derived active pharmaceutical ingredients (API) portfolio.
CB21 Pharma, a leading Czech-based pharmaceutical company specializing in producing cannabinoid ingredients and medical devices, has successfully extended its EU Good Manufacturing Practice (GMP) certification under certificate # sukls105303/2023. This achievement allows CB21 Pharma, the spin-off sister company to pioneering CBDepot, to continue manufacturing Active Pharmaceutical Ingredients (APIs) such as Cannabidiol (CBD), from initial extraction to the production of full spectrum distilled and standardized extracts from medicinal cannabis, marketed as Cannabis Extractum Raffinatum and Cannabis Extractum Normatum.